Supply Chain Management:

•Development and validation of analytical methods to ensure accurate quantification, purity assessment, and impurity profiling. 

•Characterization of raw materials, intermediates, and final APIs using techniques such as HPLC, GC, MS, NMR, and XRPD. 

•Stability studies and fo...

•Flexible and Scalable Manufacturing – Multi-purpose facilities with 50L to 5000L vessels, supporting kilo to MT batch sizes across all API development phases, from preclinical, clinical to commercial launch. Ability to synthesize 100 ton production of materials in minutes. 

•Commitment to...

•Small-scale synthesis of reference compounds, chemical intermediates, and active pharmaceutical ingredients (APIs). 

•Rapid synthesis of hit and lead compounds for drug discovery and proof of concept (PoC) studies. 


•Multi-step complex synthesis of novel molecules includi...

•Evaluating multiple synthetic pathways to determine the most efficient, cost-effective, and scalable route. 

•Assessing raw material availability and sustainability to ensure a reliable and cost-efficient supply chain. 


 •Developing innovative strategies to minimize h...

AcceleDev continues to expand its global capabilities, providing tailored solutions for clients worldwide. In addition to our New Jersey US R&D site, we also have the following China operations: 
• Shanghai - R&D Center 
• Jiangyin - Scale-up & commercial production 
• Dalian - Scale-up & commercial production 
• Nanjing - Sourcing & supply chain management 

This whitepaper, AcceleDev: Advancing Innovation and Efficiency in Unnatural Amino Acid (UAA) Synthesis, explores the growing impact of UAAs in next-generation pharmaceuticals, highlighting their role in improving drug performance, stability, and targeted delivery. It outlines the expanding global market, projected to surpass $12 billion by 2032, while addressing key challenges—cost, scalability, and regulatory barriers—that hinder commercialization. AcceleDev’s proven expertise in cost-effective and scalable UAA synthesis is showcased through detailed case studies, demonstrating successful outcomes in green chemistry, high-yield processes, and complex molecule production. With over 10,000 completed synthesis projects and robust regulatory readiness, AcceleDev positions itself as a critical partner for biotech and pharma companies aiming to bring innovative UAA-based therapies to market.

AcceleDev proudly supports your pharmaceutical innovation with our state-of-the-art facilities in Cranbury, NJ and Shanghai, China.